2,718 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Purchased by Choreo LLC

Choreo LLC bought a new position in ICU Medical, Inc. (NASDAQ:ICUI) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,718 shares of the medical instruments supplier’s stock, valued at approximately $313,000.

A number of other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its holdings in ICU Medical by 14.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock worth $19,227,000 after acquiring an additional 23,816 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of ICU Medical by 37.8% in the fourth quarter. Principal Financial Group Inc. now owns 107,335 shares of the medical instruments supplier’s stock worth $10,706,000 after purchasing an additional 29,464 shares during the last quarter. Scout Investments Inc. lifted its holdings in shares of ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after purchasing an additional 7,272 shares in the last quarter. Wakefield Asset Management LLLP bought a new stake in ICU Medical in the 1st quarter worth about $989,000. Finally, Vanguard Group Inc. raised its position in ICU Medical by 14.8% in the 4th quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock worth $243,438,000 after buying an additional 315,103 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. KeyCorp raised their price target on shares of ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Raymond James raised their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $149.00.

ICU Medical Stock Down 1.8 %

ICUI opened at $176.29 on Wednesday. ICU Medical, Inc. has a 1-year low of $78.28 and a 1-year high of $181.87. The firm’s 50 day simple moving average is $145.63 and its two-hundred day simple moving average is $119.57. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $4.30 billion, a PE ratio of -72.03 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. ICU Medical’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 earnings per share. As a group, equities analysts forecast that ICU Medical, Inc. will post 3.76 EPS for the current year.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,320,691.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares in the company, valued at $645,901.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,552 shares of company stock worth $4,537,802. 6.70% of the stock is owned by company insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.